Journal: Pharmacoeconomics

Article Title: Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review

doi: 10.1007/s40273-023-01292-5

Figure Lengend Snippet: Overview of study characteristics, clinical applications, evaluated strategies, and overall judgement

Article Snippet: 10 , Deibel et al. (2021) [ ] , CEA/CUA (USA) , Screening and early detection General population from birth until either mortality or reaching the upper age limit of 100 years , Methylated SEPT9 DNA , Epi proColon (methylated SEPT9 DNA) Other strategies (no screening, colonoscopy, FIT, ColoGuard, and PolypDx) , Cost-effective Epi proColon was cost-effective compared with no screening, with a 100% adherence scenario; Epi proColon was cost-effective compared with no screening, colonoscopy, or FIT (2 years), with real-world adherence scenario; Epi proColon was dominated compared with ColoGuard in both scenarios..

Techniques: Biomarker Discovery, Selection, Clinical Proteomics, Mutagenesis, Methylation, Adjuvant, Marker, Imaging, Spectroscopy

Journal: Clinical Epigenetics

Article Title: Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients

doi: 10.1186/s13148-017-0425-4

Figure Lengend Snippet: Training cohort. Methylation levels of SEPT9 , SHOX2 , and mean SEPT9 / SHOX2 in plasma of HNSCC ( n = 137) and control ( n = 170) patients in relative quantification, genome equivalents (absolute quantification), and quasi-digital PCR with sensitivity (sens.), specificity (spec.), and cutoffs. Receiver Operating Characteristics with AUCs of HNSCC and control patients

Article Snippet: DD has been an employee and is a consultant of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Methylation, Clinical Proteomics, Control, Quantitative Proteomics, Digital PCR

Journal: Clinical Epigenetics

Article Title: Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients

doi: 10.1186/s13148-017-0425-4

Figure Lengend Snippet: Testing cohort. Methylation levels of SEPT9 , SHOX2 , and mean SEPT/SHOX2 in plasma of HNSCC ( n = 141) and control ( n = 102) patients in relative quantification, genome equivalents (absolute quantification), and quasi-digital PCR with sensitivity (sens.), specificity (spec.), and cutoffs. ROC curves with AUCs of HNSCC and control patients

Article Snippet: DD has been an employee and is a consultant of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Methylation, Clinical Proteomics, Control, Quantitative Proteomics, Digital PCR

Journal: Clinical Epigenetics

Article Title: Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients

doi: 10.1186/s13148-017-0425-4

Figure Lengend Snippet: Training cohort. Kaplan-Meier analysis of overall survival in HNSCC patients ( n = 129). Patients are stratified according to SHOX2 and SEPT9 plasma methylation levels. Plasma methylation levels were quantified using relative, absolute quantification, and quasi-digital PCR and dichotomized based on cutoffs that resulted in specificities and sensitivities as seen in Figs. and . Cutoff values for positive (above cutoff) and negative (below cutoff) classification: SEPT9 , SHOX2 , and mean SEPT9/SHOX2 . Cutoffs for relative quantification were SEPT9 = 0.055%, SHOX2 = 0.281%, and mean SEPT9/SHOX2 = 0.118%; for absolute quantification SEPT9 = 4.68 pg, SHOX2 = 22.7 pg, and mean SEPT9/SHOX2 = 14.3 pg; for quasi-digital PCR for SEPT9 > 2, for SHOX2 > 4 and for mean SEPT9/SHOX2 > 2 positive PCR reactions

Article Snippet: DD has been an employee and is a consultant of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Clinical Proteomics, Methylation, Quantitative Proteomics, Digital PCR

Journal: Clinical Epigenetics

Article Title: Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients

doi: 10.1186/s13148-017-0425-4

Figure Lengend Snippet: Testing cohort. Kaplan-Meier analysis of overall survival in HNSCC patients ( n = 137). Patients are stratified according to SHOX2 and SEPT9 plasma methylation levels. Plasma methylation levels were quantified using relative, absolute quantification and quasi-digital PCR and dichotomized based on cutoffs established in the training cohort. Cutoff values for positive (above cutoff) and negative (below cutoff) classification: SEPT9 , SHOX2 , and mean SEPT9/SHOX2 . Cutoffs for relative quantification were SEPT9 = 0.055%, SHOX2 = 0.281%, and mean SEPT9/SHOX2 = 0.118%; for absolute quantification SEPT9 = 4.68 pg, SHOX2 = 22.7 pg, and mean SEPT9/SHOX2 = 14.3 pg; for quasi-digital PCR for SEPT9 > 2, for SHOX2 > 4, and for mean SEPT9/SHOX2 > 2 positive PCR reactions

Article Snippet: DD has been an employee and is a consultant of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Clinical Proteomics, Methylation, Quantitative Proteomics, Digital PCR

Journal: Clinical Epigenetics

Article Title: Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients

doi: 10.1186/s13148-017-0425-4

Figure Lengend Snippet: Diagnostic and prognostic performance of SHOX2 and SEPT9 hypermethylation

Article Snippet: DD has been an employee and is a consultant of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Diagnostic Assay, Biomarker Discovery

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Clinicopathological data of 71 biliary tract cancer patients included in the tissue study. Associations of clinicopathological data with relative DNA methylation of SHOX2 and SEPT9 in tumor tissue

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: DNA Methylation Assay, Methylation, Biomarker Discovery

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: SHOX2 and SEPT9 DNA methylation levels in tissue samples. Relative DNA methylation values (PMR in %) of SHOX2 are depicted as black rhombuses for a NAT and BTC specimens, as well as for b NAT, CC, and GBC specimens. PMR values of SEPT9 are also depicted for c NAT and BTC specimens, as well as for d NAT, CC, and GBC specimens. Horizontal lines indicate median PMR values of sample series. p values refer to Mann-Whitney U test. *Bonferroni corrected p values for multiple pairwise compare

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: DNA Methylation Assay, MANN-WHITNEY

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves for SHOX2 , SEPT9 , and the combined biomarker panel (based on the sum of PMR values) in tissue specimens. The ROC curves and resulting area under the curve (AUC) values are depicted for a all 55 BTC specimens: AUC— SHOX2 = 0.918 [95% CI 0.865–0.971]; AUC— SEPT9 = 0.601 [95% CI 0.488–0.713]; AUC—Panel 0.933 [95% CI 0.886–0.979] b 43 CC specimens: AUC— SHOX2 = 09.21 [0.863–0.979]; AUC— SEPT9 = 0,.541 [95% CI 0.416–0.666]; AUC—Panel = 0.932 [95% CI 0.880–0.984] and c 12 GBC specimens: AUC— SHOX2 = 0.907 [95% CI 0.808–1.005]; AUC— SEPT9 = 0.815 [95% CI 0.637–0.993]; AUC—Panel = 0.935 [95% CI 0.855–1.015], respectively

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Biomarker Discovery

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Results from univariate and multivariate survival analyses (Cox proportional hazard models)

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Biomarker Discovery, Methylation

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Relative DNA methylation values (PMR in %) of a SHOX2 and b SEPT9 in plasma samples from 100 controls and 20 cholangiocarcinoma patients. Each black rhombus represents a patient sample. Horizontal lines indicate median PMR values of sample series. p values refer to Mann-Whitney U test

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: DNA Methylation Assay, Clinical Proteomics, MANN-WHITNEY

Journal: Clinical Epigenetics

Article Title: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

doi: 10.1186/s13148-016-0299-x

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves and area under the curve (AUC) values for SHOX2 , SEPT9 , and the combined biomarker panel, based on the sum of PMR values, in plasma samples. AUC— SHOX2 = 0.691 [95% CI 0.554–0.828]; AUC- SEPT9 = 0.699 [95% CI 0.561–0.837]; AUC-Panel = 0.752 [95% CI 0.631–0.873]

Article Snippet: Dimo Dietrich has been an employee and is a stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2 .

Techniques: Biomarker Discovery, Clinical Proteomics

Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Age plotted against Sept9 outcome. FP: False positive, TN: True negative, FN: False negative, TP: True positive. N: Number of subjects in each category. Age: All ages younger or equal to the age interval mentioned. -1/3 and 2/3 refers to the PCR-algorithms used

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques:

Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Sept9 positivity of individuals with CRC

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques: Clinical Proteomics

Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Sept9 positivity of individuals with NED

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques: Clinical Proteomics

Journal: BMC Cancer

Article Title: Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study

doi: 10.1186/s12885-015-1832-6

Figure Lengend Snippet: Predictors of Colorectal Cancer, 1/3 algorithm

Article Snippet: Samples were then analyzed for presence of methylated Sept9 DNA with the Sensitive PCR kit on a 7500 Fast Dx Real Time PCR device (Life Technologies).

Techniques: